Sonoma Biotherapeutics and Regeneron Announce $120M Collaboration for Cell Therapies for Autoimmune Diseases

Regeneron Pharmaceuticals, a leading biotech company that invents, develops, and commercializes medicines, has collaborated with Sonoma Biotherapeutics, a clinical-stage biotech company developing engineered regulatory T cell (T_reg) therapies to treat serious autoimmune and inflammatory diseases.

 T_reg cells act as sentinels that act as an indicator of the presence of diseases and rebalance the immune system. Emerging research highlights how T_reg cells work directly at the site of inflammation – having the potential to create a long-lasting response.

“We are thrilled to collaborate with Regeneron with the goal of developing best-in-class T_reg therapies for ulcerative colitis, Crohn’s, and other diseases,” said Jeff Bluestone, Ph.D., Co-founder and CEO of Sonoma Biotherapeutics.

How are you enjoying this news article? Let us know your thoughts, here >>

The partnership will utilize Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T cell receptors with Sonoma Biotherapeutics’ pioneering approach to developing and manufacturing gene-modified T_reg cell therapies. 

Jeff also adds, “Regeneron has a track record of seeking out pioneers in their fields and forging successful partnerships. This collaboration will combine Regeneron’s proven technology and clinical expertise with Sonoma Bio’s proprietary T_reg platform and T_reg research enterprise to develop therapies that restore balance to the immune system and potentially cure disease.”

T_regs as a therapeutic modality has the ability to acquire multiple therapeutic effects, transforming treatments, within a single medicine, helping overcome the multifaceted nature of autoimmune and inflammatory diseases. 

Source: Regeneron Press Release 

While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.